-+ 0.00%
-+ 0.00%
-+ 0.00%

AEON Biopharma Announces Two Complementary Transaction Of ~$22M, Eliminating Nearly All Debt

Benzinga·11/13/2025 13:40:58
Listen to the news

AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX® (onabotulinumtoxinA) biosimilar, today announced two complementary transactions totaling up to ~$22 million in potential proceeds that will collectively transform the Company's balance sheet, eliminate nearly all outstanding debt, and provide capital to accelerate program execution ahead of AEON's upcoming FDA Type 2a meeting.